CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Trovagene expects to achieve analytical and clinical validation of its urine-based HPV carrier screening test this month in its CLIA laboratory. When validation is complete, the test will be available to clinicians and their patients.
In addition to ongoing HPV validation studies, one clinical trial has been completed in India and two additional trials are underway in collaboration with the Barretos Cancer Center, Brazil, and Strand Life Sciences, India.
Trovagene has extended its planned offering of urine-based oncogene mutation tests for 2013 to include a test for the detection of a specific p53 mutation and specific double mutation in the hepatitis B virus. Both markers are strongly associated with hepatocellular carcinoma (HCC). Availability of the HCC test is anticipated in the fourth quarter this year. Trovagene expects to introduce its KRAS oncogene mutation test mid-year.
Trovagene, 858-952-7570